UNICA IRIS Institutional Research Information System

ORIGA, RAFFAELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 111.638
NA - Nord America 7.155
AS - Asia 2.929
SA - Sud America 670
AF - Africa 68
OC - Oceania 8
Totale 122.468
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 108.594
US - Stati Uniti d'America 7.043
SG - Singapore 1.141
CN - Cina 1.116
NL - Olanda 1.108
BR - Brasile 579
SE - Svezia 560
UA - Ucraina 444
DE - Germania 297
VN - Vietnam 241
GB - Regno Unito 179
FI - Finlandia 165
CA - Canada 65
IN - India 64
FR - Francia 62
KR - Corea 42
AT - Austria 40
TR - Turchia 38
BD - Bangladesh 37
RU - Federazione Russa 35
HK - Hong Kong 30
IQ - Iraq 30
AR - Argentina 29
ES - Italia 27
PK - Pakistan 27
IR - Iran 26
MX - Messico 26
ZA - Sudafrica 25
BE - Belgio 22
EC - Ecuador 20
ID - Indonesia 17
JP - Giappone 16
PL - Polonia 15
AE - Emirati Arabi Uniti 13
UZ - Uzbekistan 13
MA - Marocco 12
MY - Malesia 12
TH - Thailandia 12
CO - Colombia 11
EG - Egitto 10
IL - Israele 10
LT - Lituania 10
RO - Romania 10
SI - Slovenia 10
BG - Bulgaria 8
JO - Giordania 8
VE - Venezuela 8
CH - Svizzera 7
KE - Kenya 7
CL - Cile 6
PT - Portogallo 6
PY - Paraguay 6
AU - Australia 5
GR - Grecia 5
HU - Ungheria 5
IE - Irlanda 5
PE - Perù 5
TN - Tunisia 5
TW - Taiwan 5
BO - Bolivia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
HN - Honduras 4
JM - Giamaica 4
SA - Arabia Saudita 4
AL - Albania 3
AZ - Azerbaigian 3
CY - Cipro 3
GT - Guatemala 3
KZ - Kazakistan 3
NP - Nepal 3
NZ - Nuova Zelanda 3
BH - Bahrain 2
CR - Costa Rica 2
EE - Estonia 2
LB - Libano 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
UY - Uruguay 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GM - Gambi 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
ML - Mali 1
Totale 122.460
Salva come PNG Salva come JPEG
Città #
Cagliari 104.354
Uta 2.942
Amsterdam 1.086
Woodbridge 679
Fairfield 635
Ashburn 561
Chandler 526
Singapore 518
Dallas 387
Boardman 366
Houston 365
Nyköping 352
Ann Arbor 293
Beijing 270
Wilmington 269
Seattle 216
Cambridge 209
Jacksonville 184
Dearborn 178
Los Angeles 141
Santa Clara 130
Chicago 129
Milan 117
Boston 108
Rome 108
Shanghai 98
Buffalo 97
Nanjing 89
Hefei 82
Helsinki 77
Ho Chi Minh City 72
Dong Ket 64
San Diego 54
New York 53
Salt Lake City 51
The Dalles 48
Redondo Beach 42
Guangzhou 40
São Paulo 40
Naples 39
Seoul 38
Nuremberg 36
Council Bluffs 33
Hanoi 32
Munich 30
Tampa 28
Hebei 27
London 27
Redwood City 27
Sassari 26
Toronto 26
Brooklyn 24
Hong Kong 24
Elk Grove Village 23
Shenyang 23
Brussels 21
Bari 20
Changsha 20
Turin 20
Vienna 20
Nanchang 19
Phoenix 19
Tianjin 19
Florence 18
Mountain View 17
Salvador 17
Frankfurt am Main 16
Jiaxing 16
Jinan 16
Montreal 16
Rio de Janeiro 16
Curitiba 15
Columbus 14
Livorno 14
Tokyo 14
Denver 13
Seregno 13
Verona 13
Warsaw 13
Atlanta 12
Catania 12
Johannesburg 12
Zhengzhou 12
Bologna 11
Düsseldorf 11
Genoa 11
Lappeenranta 11
Padova 11
Porto Alegre 11
Pune 11
Ankara 10
Baghdad 10
Belo Horizonte 10
Gavirate 10
Gurgaon 10
Istanbul 10
Mexico City 10
Norwalk 10
Orange 10
Palermo 10
Totale 117.117
Salva come PNG Salva come JPEG
Nome #
Thalassemia major between liver and heart: Where we are now 4.061
Current growth patterns in children and adolescents with thalassemia major 2.970
A decisional algorithm to start iron chelation in patients with beta thalassemia 2.884
A genetic score for the prediction of beta-thalassemia severity 2.863
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia 2.679
Deferasirox and children: From clinical trials to the real world 2.455
The V736A TMPRSS6 polymorphism influences liver iron concentration in non-transfusion-dependent thalassemias 2.336
Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation 2.237
IFNL3 polymorphisms and HCV infection in patients with beta thalassemia 2.147
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.117
Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015 2.056
Thalassemia major: who is afraid of serum ferritin below 500 μg/l? 2.002
The problem of borderline hemoglobin A2 levels in the Screening for β-thalassemia carriers in Sardinia. 2.001
Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment 1.958
Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study 1.944
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia 1.881
Investigating the Alpha 1Ncol mutation 1.845
null 1.759
Hematological phenotypes in children according to the α-globin genotypes 1.755
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.690
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.627
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia 1.509
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major 1.506
Deferasirox: pharmacokinetics and clinical experience 1.422
β-Thalassemia 1.422
Nuovi farmaci ferrochelanti e nuove strategie di ferro chelazione nella talassemia major 1.387
A complicated disease: What can be done to manage thalassemia major more effectively? 1.316
Alpha-Thalassemia 1.315
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia 1.299
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload 1.289
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload 1.265
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major 1.258
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA 1.176
Prospettive in Pediatria 1.151
Clinical and molecular analysis of haemoglobin H disease in Sardinia: Haematological, obstetric and cardiac aspects in patients with different genotypes 1.151
Polymorphism of S-transferase glutathione gene and a major thalassaemia cardiac iron 1.135
Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice. 1.119
Combined therapy with deferiprone and desferrioxamine in thalassemia major 1.048
Glutathione S-transferase se gene polymorphism and heart iron overload in Thalassemia major 1.032
null 1.009
Lack of heart iron overload in patients with thalassemia intermedia. 996
Onset of cardiac iron loading in pediatric patients 984
null 886
Urinary hepcidin in thalassemic syndromes 883
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up 872
Risk factors for haemorrhagic cystitis in beta thalassemic patients undergoing allogeneic haematopoietic stem cell transplant 860
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia 848
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major 814
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up 809
Pregnancy in Thalassemia 781
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox 765
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 752
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort 745
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia 737
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study 729
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia 718
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA 710
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study 689
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis 687
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment 682
Changing patterns of thalassaemia in Italy: a WebThal perspective. 681
Beta-thalassemia 677
Genetic basis, pathophysiology and diagnosis 672
DEFERASIROX-DEFEROXAMINE COMBINATION THERAPY REDUCES CARDIAC IRON WITH RAPID LIVER IRON REMOVAL AFTER 24 MONTHS IN PATIENTS WITH SEVERE TRANSFUSIONAL IRON OVERLOAD (HYPERION) 667
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (beta)-Thalassemia: Interim Results 665
Retrospective evaluation of different iron chelators on cardiac T2* 658
Pathophysiology of beta thalassaemia 653
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions 648
Beta-Thalassemia. 639
Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects 632
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias 630
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021 628
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias 627
Pregnancy and β-thalassemia: An Italian multicenter experience 621
null 618
Deferasirox-Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION) 600
null 589
Cholelithiasis in thalassemia major 588
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial 586
Lack of correlation between serum ferritin and liver iron concentration in beta-zero thalassemia intermedia 577
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia 565
Sudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia [5] 564
Neutropenia in patients with thalassemia major. 555
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS) 555
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited 552
GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia 547
Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey 544
null 539
Phenoconversion’ in adult patients with β-thalassemia 533
Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC) 522
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations 521
Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm 516
Prima e dopo la splenectomia: terapia combinata in un paziente con compromissione cardiaca secondaria all'accumulo di ferro. 510
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies" 504
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study 497
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 488
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization 485
The Management of Endocrine Complications in Patients with Haemoglobinopathies: Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) 473
Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy 458
Densità minerale ossea e rischio di frattura nella _ talassemia major 455
Totale 110.062
Salva come PNG Salva come JPEG
Categoria #
all - tutte 169.770
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 169.770
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217.505 0 0 0 0 0 1.885 1.322 973 413 836 991 1.085
2021/20228.150 715 540 416 589 916 841 360 487 508 817 1.092 869
2022/202311.368 1.034 1.395 1.223 756 1.008 953 471 1.504 723 737 1.026 538
2023/202413.514 644 557 523 952 1.107 2.317 2.438 854 655 1.002 1.156 1.309
2024/202524.749 4.381 4.815 4.101 3.125 1.580 1.876 1.983 153 416 1.342 692 285
2025/20263.610 714 343 908 696 581 368 0 0 0 0 0 0
Totale 123.026